The AZTherapies team shares a practical, innovative, entrepreneurial, and mission-driven approach to bringing therapeutics to patients more quickly, safely, and affordably.
Advancing a growing pipeline of candidates to treat patients with few therapeutic options, our lead program, ALZT-OP1, is built on a multi-modal approach that recognizes neuroinflammation as a root cause of serious neurodegeneration and seeks to stop or slow the progression of disease. Our Phase 3 COGNITE trial in early Alzheimer’s disease completed in late 2020. Following our lead program, we are advancing candidates for the treatment of amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.
AZTherapies is a private company headquartered in Boston, Massachusetts.
AZTherapies At A Glance
Board of Directors
Ronald G. Tompkins, M.D., Sc.D.
Steven L. Wagner, Ph.D.